Selective Inhibitor Development, Resistance Mechanisms, and High-Purity Reagents for Lymphoma Therapeutics.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for EZH2 Y641N drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Mutant Antigen | EZH2 Y641N Recombinant Protein (SET Domain / Full Length) High purity (>95%), Endotoxin <1 EU/µg. Sequence Verified. Theoretical MW confirmed. HEK293 or E. coli expression available. |
View EZH2 Y641N Products |
| PRC2 Complex | Pre-assembled PRC2 Complex (Y641N-EZH2 / EED / SUZ12 / RbAp48 / AEBP2) For physiologic methyltransferase assays. High purity, endotoxin controlled. |
View EZH2 Y641N Products |
| Wild-Type Counter-Screen | EZH2 WT Recombinant Protein For selectivity profiling against wild-type enzyme. Sequence Verified. |
View EZH2 Products |
| Gene Delivery | EZH2 Y641N Promise-ORF / Lentivirus Full-length mutant ORF for stable cell line construction. Sequence Verified. |
View EZH2 Y641N Products |
| Benchmark Ab | Anti-EZH2 (Recombinant Rabbit mAb) Positive control for Western, IP, and IHC. Sequence Verified. |
View EZH2 Y641N Products |
| Validator | EZH2 siRNA Set For knockdown and specificity verification in cellular assays. |
View EZH2 Y641N Products |
| Related Target A | EED Core PRC2 subunit; allosteric inhibitor target and complex stabilizer. |
View EED Products |
| Related Target B | SUZ12 Essential PRC2 component; required for EZH2 methyltransferase activity. |
View SUZ12 Products |
| Homolog Counter-Screen | EZH1 Recombinant Protein Closest homolog; critical for dual-selectivity profiling. |
View EZH1 Products |
| Substrate | Histone H3.3 Recombinant Protein Unmodified H3 substrate for methylation assays. High purity (>95%). |
View H3.3 Products |
TarMart Assay Advantage Table
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Mutant vs WT Selectivity (Y641N altered substrate preference) | Purified Y641N and WT proteins with matched endotoxin levels (<1 EU/µg) for parallel screening |
| Physiologic Substrate Requirement (nucleosome vs peptide) | PRC2 pre-assembled complex with native partners; validated for H3K27me3 on nucleosomes |
| EZH1 Homolog Counter-Screening | EZH1 recombinant protein strictly verified by mass spec for off-target evaluation |
| Cellular Target Engagement (H3K27me3 modulation) | Lentivirus particles for stable Y641N knock-in or overexpression; endotoxin controlled |
| Lack of Assay Controls | Clinical benchmark small-molecule inhibitors available as reference standards; EZH2 siRNA included |
| PRC2 Complex Assembly (EED/SUZ12 dependency) | Individual recombinant components (EED, SUZ12) for reconstituted functional assays |
| Resistance Profiling (Y641F, A677G) | Additional mutant proteins available (Y641F, A677G) for resistance mechanism studies |
Live EZH2 Y641N R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for EZH2 Y641N therapeutics is intensifying, with first-generation pan-EZH2 inhibitors like tazemetostat (Tazverik, Ipsen) achieving FDA approval for EZH2-mutated follicular lymphoma and epithelioid sarcoma. However, clinical use is limited by dose-limiting toxicities (e.g., thrombocytopenia) due to WT EZH2 inhibition. The next wave of R&D is shifting toward mutant-selective small molecules that spare WT EZH2, targeted protein degraders (PROTACs) to overcome acquired resistance, and allosteric inhibitors targeting EED. Key resistance mutations include Y641F and A677G, which alter the inhibitor binding pocket. Combination strategies with BCL2 inhibitors (venetoclax) and PI3K inhibitors are being explored in DLBCL models. The pipeline is also expanding into solid tumors with SMARCB1/INI1 loss, where EZH2 dependency creates synthetic lethality.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors (Pan-EZH2) | Ipsen (Epizyme), Pfizer | Follicular Lymphoma, DLBCL | Selectivity Assay (Need Y641N vs WT proteins) |
| Mutant-Selective Inhibitors | Daiichi Sankyo, Constellation | Resistant Lymphomas | Resistance Panel (Y641N, Y641F, A677G mutants) |
| PROTACs / Degraders | Arvinas, Cullgen | Refractory Lymphomas | Ternary Complex Formation (Need High-Purity EZH2/EED) |
| Allosteric Inhibitors (EED-targeted) | Novartis, Pfizer | Solid Tumors (EED/EZH2 axis) | Complex Activity Assay (Need PRC2 components) |
| PRC2 Disruptors | Various Biotech | Solid Tumors | Complex Assembly (Need EED/SUZ12 recombinant proteins) |
Molecular Biology of EZH2 Y641N
EZH2 Y641N is a point mutation in the SET domain (Tyr641Asn). According to UniProt (Q15910), this mutation (dbSNP rs193921148) is associated with decreased histone methyltransferase activity in the context of WVS. However, in follicular lymphoma and DLBCL, Y641N is a recurrent gain-of-function mutation that alters substrate specificity, leading to aberrant H3K27me3 accumulation. The mutation shifts the enzyme's preference from H3K27me2 to H3K27me1/me2, promoting trimethylation and silencing tumor suppressor genes. This paradox underscores the need for careful selectivity profiling in drug development.